<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479401</url>
  </required_header>
  <id_info>
    <org_study_id>248.524</org_study_id>
    <secondary_id>Eudract No 2007-000073-39</secondary_id>
    <nct_id>NCT00479401</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients</brief_title>
  <official_title>A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to
      determine the efficacy (as measured by the change from baseline to the end of the maintenance
      phase in the total score for the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II
      and III combined), safety, and tolerability of Pramipexole Extended Release (ER) (in daily
      doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority
      between the two formulations (ER and IR) of pramipexole.

      In addition, the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo,
      for assay sensitivity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score</measure>
    <time_frame>baseline and after 33 weeks treatment</time_frame>
    <description>Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale</measure>
    <time_frame>after 18 weeks of treatment compared to baseline</time_frame>
    <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale</measure>
    <time_frame>after 18 weeks of treatment compared to baseline</time_frame>
    <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II+III Responder Rate (at Least 20% Improvement)</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part I Change From Baseline</measure>
    <time_frame>baseline and after 33 weeks treatment</time_frame>
    <description>UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part II Total Score</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part III Total Score</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory Version I A</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Scale for Pain Related to PD</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Sleep Scale (PDSS)</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include:
mobility (e.g. fear of falling when walking): 10 items
activities of daily living (e.g. difficulty cutting food): 6 items
emotional well-being (e.g. feelings of isolation): 6 items
stigma (e.g. social embarrassment): 4 items
social support: 3 items
cognition: 4 items
communication: 3 items
bodily discomfort: 3 items.
A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life Visual Analog Scale</measure>
    <time_frame>after 33 weeks treatment</time_frame>
    <description>European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Started to Use L-Dopa Rescue Medication</measure>
    <time_frame>from trial start on to any time before final assessment of the patient, up to 33 weeks</time_frame>
    <description>L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)</measure>
    <time_frame>from trial start on to any time before final assessment of the patient, up to 33 weeks</time_frame>
    <description>mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible Clinically Significant Abnormal Laboratory Parameters</measure>
    <time_frame>baseline and after 33 weeks of treatment</time_frame>
    <description>The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events</measure>
    <time_frame>baseline and after 33 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Early Parkinson Disease (Early PD)</condition>
  <arm_group>
    <arm_group_label>Pramipexole Extended Release (PPX ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole Immediate Release (PPX IR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexol Extended Release</intervention_name>
    <arm_group_label>Pramipexole Extended Release (PPX ER)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexol Immediate Release</intervention_name>
    <arm_group_label>Pramipexole Immediate Release (PPX IR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient with idiopathic Parkinsons disease (PD) confirmed by at least
             two of the following signs: resting tremor, bradykinesia, rigidity.

          2. Parkinsons disease diagnosed within 5 years.

          3. Patients 30 years of age or older at the time of diagnosis.

          4. Modified Hoehn and Yahr stage of 1 to 3.

          5. Patients requiring additional therapy/ introduction of therapy (for de novo patients)
             to treat their parkinsonian symptoms at the time of enrollment (screening visit, V1)
             according to the investigators judgement.

        Exclusion Criteria:

          1. Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine),
             metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases
             (e.g., progressive supranuclear palsy).

          2. Dementia, as defined by a Mini-Mental State Exam score &lt; 24 at screening visit

          3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental
             Disorders 4th (DSM-IV)

          4. History of psychosis

          5. Clinically significant electrocardiogram (ECG) abnormalities at screening visit

          6. Clinically significant hypotension

          7. Malignant melanoma or history of previously treated malignant melanoma

          8. Any other clinically significant disease, whether treated or not, that could put the
             patient at risk or could prevent compliance or completion of the study

          9. Pregnancy

         10. Sexually active female of childbearing potential not using a medically approved method
             of birth control

         11. Serum levels of Aspartate Aminotransferase (AST) , Alanine Aminotransferase (ALT),
             alkaline phosphatases or bilirubin &gt; 2 Upper Limit of Normal (ULN)

         12. Patients with a creatinine clearance &lt; 50 mL/min

         13. Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit,
             or L-Dopa within 8 weeks prior to baseline visit.

         14. Total cumulative duration of prior exposure to Levodopa of more than 3 months.

         15. Any medication (including intra-muscular formulations) with central dopaminergic
             antagonist activity within 4 weeks prior to the baseline visit

         16. Any of the following drugs within 4 weeks prior to the baseline visit:
             methylphenidate, cinnarizine, amphetamines.

         17. Flunarizine within 3 months prior to baseline visit

         18. Known hypersensitivity to Pramipexole or its excipients

         19. Drug abuse (including alcohol), according to Investigators judgement, within 2 years
             prior to screening.

         20. Participation in other investigational drug studies or use of other investigational
             drugs within one month or five times the half-life of the investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.524.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54008 Instituto de Neurociencias de Buenos Aires</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aomori, Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuchu, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fujisawa, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwamizawa,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kodaira, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ota-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimogyo-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiroishi, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubnica nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytzya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.524.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>November 20, 2009</results_first_submitted>
  <results_first_submitted_qc>March 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2010</results_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pramipexole Extended Release (PPX ER)</title>
          <description>PPX ER tablets taken once in the morning</description>
        </group>
        <group group_id="P2">
          <title>Pramipexole Immediate Release (PPX IR)</title>
          <description>PPX IR tablets taken three times a day</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo to PPX ER once and to PPX IR three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria, relocation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pramipexole Extended Release (PPX ER)</title>
          <description>PPX ER tablets taken once in the morning</description>
        </group>
        <group group_id="B2">
          <title>Pramipexole Immediate Release (PPX IR)</title>
          <description>PPX IR tablets taken three times a day</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo to PPX ER once and to PPX IR three times a day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="539"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.8"/>
                    <measurement group_id="B2" value="61.7" spread="9.6"/>
                    <measurement group_id="B3" value="62.0" spread="9.6"/>
                    <measurement group_id="B4" value="61.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score</title>
        <description>Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.</description>
        <time_frame>baseline and after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score</title>
          <description>Activities of daily living are scored from 0-52 in UPDRS II, result of motor examination scored 0-108 in UPDRS III. A decrease in the score means improvement.</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-9.9" upper_limit="-7.2"/>
                    <measurement group_id="O2" value="-8.8" lower_limit="-10.2" upper_limit="-7.4"/>
                    <measurement group_id="O3" value="-3.8" lower_limit="-5.9" upper_limit="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A non-inferiority hypothesis (H0: μER - μIR &lt; -3 vs. H1: μER - μIR ≥ -3) comparing pramipexole ER to pramipexole IR was tested using a non-inferiority margin of -3 points.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority hypothesis comparing pramipexole ER to pramipexole IR was to be tested using a non-inferiority margin of -3 points. The primary efficacy endpoint in UPDRS part II+III was the change from baseline (week 0) to week 33 on the UPDRS Parts II+III score combined. The statistical model was analysis of covariance, controlling for baseline UPDRS Part II+III. Fixed terms in the model were treatment, country, and UPDRS Part II+III score at baseline.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>PPX ER non−inferior to PPX IR, if the lower limit of the confidence interval for the difference is higher than the non−inferiority margin of −3</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale</title>
        <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale</description>
        <time_frame>after 18 weeks of treatment compared to baseline</time_frame>
        <population>Full Analysis Set 1, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment and completed 18 weeks of treatment or discontinued prematurely at the interim cut off date Apr 2008</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders on the Clinical Global Impressions of Improvement (CGI-I) Scale</title>
          <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. Responders are the patients with 'much improved' and 'very much improved' on the scale</description>
          <population>Full Analysis Set 1, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment and completed 18 weeks of treatment or discontinued prematurely at the interim cut off date Apr 2008</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale</title>
        <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.</description>
        <time_frame>after 18 weeks of treatment compared to baseline</time_frame>
        <population>Full Analysis Set 1, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment and completed 18 weeks of treatment or discontinued prematurely at the interim cut off date Apr 2008</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders on the Patients Global Impressions of Improvement (PGI-I) Scale</title>
          <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. Responders are the patients with 'much better' and 'very much better' on the score.</description>
          <population>Full Analysis Set 1, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment and completed 18 weeks of treatment or discontinued prematurely at the interim cut off date Apr 2008</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS II+III Responder Rate (at Least 20% Improvement)</title>
        <description>Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS II+III Responder Rate (at Least 20% Improvement)</title>
          <description>Responders are defined as at least 20% decrease in the UPDRS II+III score. UPDRS II+III ranges 0-160 scores from best to worse.</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                    <measurement group_id="O2" value="65.7"/>
                    <measurement group_id="O3" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part I Change From Baseline</title>
        <description>UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement</description>
        <time_frame>baseline and after 33 weeks treatment</time_frame>
        <population>Full Analysis Set with (LOCF), all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part I Change From Baseline</title>
          <description>UPDRS I evaluates mentation behaviour and mood with a total score of 0-16. Decrease in the scores means improvement</description>
          <population>Full Analysis Set with (LOCF), all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part II Total Score</title>
        <description>UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part II Total Score</title>
          <description>UPDRS II evaluates activities of daily living in a score 0-52. Decrease of the score means improvement</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-2.6" upper_limit="-1.7"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-2.9" upper_limit="-2.0"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.5" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part III Total Score</title>
        <description>UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part III Total Score</title>
          <description>UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" lower_limit="-7.4" upper_limit="-5.4"/>
                    <measurement group_id="O2" value="-6.4" lower_limit="-7.4" upper_limit="-5.4"/>
                    <measurement group_id="O3" value="-2.8" lower_limit="-4.2" upper_limit="-1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck's Depression Inventory Version I A</title>
        <description>The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Beck's Depression Inventory Version I A</title>
          <description>The Beck's Depression Inventory (BDI) is a 21-item self-rating scale that was originally designed as an instrument to assess the intensity of depressive symptoms (sadness, pessimism, sense of failure, dissatisfaction, guilt, expectation of punishment, dislike of self, self-accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, changes in body image, retardation, insomnia, fatigability, loss of appetite and weight, somatic preoccupation, low level of energy). Each item is scored from 0 (absent) to 3 (severe). The patients select the score which best describes their status in the last 7 days. Since its introduction in 1961, its use has been extended (also to PD patients) and today it is used also as a screening instrument as well as an outcome measure in depression treatment trials. The total score sums the 21 individual items yielding a score that can range from zero (minimal depression) to 63 (severe depression).</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-2.7" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-2.7" lower_limit="-3.4" upper_limit="-2.0"/>
                    <measurement group_id="O3" value="-2.1" lower_limit="-3.1" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Likert Scale for Pain Related to PD</title>
        <description>Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Likert Scale for Pain Related to PD</title>
          <description>Patient assessed 11 units on a scale from 'no pain' to 'unbearable pain'. Decrease of the score means improvement</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.4" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.4" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.2" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Sleep Scale (PDSS)</title>
        <description>PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Sleep Scale (PDSS)</title>
          <description>PDSS is a self-rated instrument addressing 15 commonly reported symptoms associated with sleep disturbance on 15 visual analogue scales (VAS: 0 to 10 cm) each ranging from worst score ('awful or always' at the left extremity to the best score ('excellent or never' at the right extremity) An increase in the score means improvement. Worst possible score 0, best score 150)</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="-0.4" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.8" upper_limit="8.4"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.8" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score</title>
        <description>The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include:
mobility (e.g. fear of falling when walking): 10 items
activities of daily living (e.g. difficulty cutting food): 6 items
emotional well-being (e.g. feelings of isolation): 6 items
stigma (e.g. social embarrassment): 4 items
social support: 3 items
cognition: 4 items
communication: 3 items
bodily discomfort: 3 items.
A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parkinson's Disease Quality of Life Questionnaire Total Score</title>
          <description>The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health which patients consider to be adversely affected by the disease. Higher scores are consistently associated with more severe symptoms of the disease such as tremor and stiffness, while lower scores indicate a better perceived health status. The 8 domains include:
mobility (e.g. fear of falling when walking): 10 items
activities of daily living (e.g. difficulty cutting food): 6 items
emotional well-being (e.g. feelings of isolation): 6 items
stigma (e.g. social embarrassment): 4 items
social support: 3 items
cognition: 4 items
communication: 3 items
bodily discomfort: 3 items.
A total score is calculated by summing the responses to the 39 individual items and the total ranges from 0 (no problem at all) to 156 (maximum level of problem). A negative change in the total score indicates improvement.</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" lower_limit="-6.1" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-8.6" upper_limit="-4.5"/>
                    <measurement group_id="O3" value="-2.1" lower_limit="-4.9" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life Visual Analog Scale</title>
        <description>European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.</description>
        <time_frame>after 33 weeks treatment</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life Visual Analog Scale</title>
          <description>European Quality of Life Visual Analog Scale (EQ-5D VAS) is a 20 centimeter vertical analog scale assessing the patient's general health status with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A positive change in the scale indicates improvement in health status.</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.4" upper_limit="7.6"/>
                    <measurement group_id="O2" value="6.6" lower_limit="3.9" upper_limit="9.2"/>
                    <measurement group_id="O3" value="3.2" lower_limit="-0.4" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Started to Use L-Dopa Rescue Medication</title>
        <description>L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population</description>
        <time_frame>from trial start on to any time before final assessment of the patient, up to 33 weeks</time_frame>
        <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Started to Use L-Dopa Rescue Medication</title>
          <description>L-dopa could be introduced as rescue medication based upon the clinical judgement of the investigator. descriptive on the Full Analysis Set (FAS) population</description>
          <population>Full Analysis Set, all randomized patients, received at least one dose of study drug and provided any post baseline efficacy assessment</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)</title>
        <description>mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).</description>
        <time_frame>from trial start on to any time before final assessment of the patient, up to 33 weeks</time_frame>
        <population>Treated Set (TS), all randomized patients, who were dispensed study medication and documented to have taken at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment Emergent Abnormal Behaviour as Indicated by the Modified Minnesota Impulsive Disorders Interview (mMIDI Questionnaire)</title>
          <description>mMIDI is a semi-structured clinical interview to assess pathological gambling (12 questions, positive screen if patient answers 'yes' to question 1 and to at least 5 of the rest of the questions), compulsive buying (9 questions from 1a to 4c, positive screen if the patient answers 'yes' to 1a, 2a, 3a, and 4a) and compulsive sexual behaviour (4 questions, positive screen if patient answers 'yes' to question 1,2,3, or 4).</description>
          <population>Treated Set (TS), all randomized patients, who were dispensed study medication and documented to have taken at least 1 dose of study medication.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Possible Clinically Significant Abnormal Laboratory Parameters</title>
        <description>The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.</description>
        <time_frame>baseline and after 33 weeks of treatment</time_frame>
        <population>Treated Set Labs (TSLabs), all patients in TS with a clinical laboratory measurements at baseline and at the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Possible Clinically Significant Abnormal Laboratory Parameters</title>
          <description>The significant abnormality of values was based on standard criteria defined in appendix 16.1.10, LISTING 4 Criteria for clinically significant abnormalities based on normalized laboratory values.</description>
          <population>Treated Set Labs (TSLabs), all patients in TS with a clinical laboratory measurements at baseline and at the last visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematocrit - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="9.8"/>
                    <measurement group_id="O2" value="3" spread="10.1"/>
                    <measurement group_id="O3" value="1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell ct. - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell ct. - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neut., poly (segs) - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neut., poly (segs), absol. - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, total - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events</title>
        <time_frame>baseline and after 33 weeks of treatment</time_frame>
        <population>Treated set (TS)</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole Extended Release (PPX ER)</title>
            <description>PPX ER tablets taken once in the morning</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole Immediate Release (PPX IR)</title>
            <description>PPX IR tablets taken three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to PPX ER once and to PPX IR three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormal Findings in Vital Signs and Physical Examination as Reported in Adverse Events</title>
          <population>Treated set (TS)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure diastolic increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from trial start on to any time before final assessment of the patient, up to 33 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pramipexole Extended Release (PPX ER)</title>
          <description>PPX ER tablets taken once in the morning</description>
        </group>
        <group group_id="E2">
          <title>Pramipexole Immediate Release (PPX IR)</title>
          <description>PPX IR tablets taken three times a day</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo to PPX ER once and to PPX IR three times a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hallucinations, mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

